Journal Article

Anticoagulation Therapy Timing in patients with Atrial Fibrillation after Acute and Chronic Subdural Haematoma (ATTAACH): a pilot randomised controlled trial

Scales, Damon, Nassiri, Farshad, Pirouzmand, Farhad, Mansouri, Alireza

2024

Overview

IntroductionSubdural haematomas (SDHs), acute or chronic, are common neurosurgical diagnoses. These problems can occur among patients requiring direct oral anticoagulation (DOAC) for atrial fibrillation. There are currently no guidelines regarding the optimal timing to resume anticoagulation for these patients after SDH. The objective of this study is to evaluate the feasibility of conducting a future large randomised controlled trial (RCT) evaluating the safety and efficacy of resuming DOACs early (ie, at 30 days) vs late (ie, at 3 months) for patients with atrial fibrillation following diagnosis of SDH.Methods and analysisThis is a pilot, open-label, multicentre RCT that will enrol adults with newly diagnosed acute or chronic SDH with or without other intracranial bleeding who were receiving therapeutic anticoagulation with a DOAC as stroke prophylaxis for atrial fibrillation. Patients will be randomly allocated to resume a DOAC at standard dosing starting either days 30+7 or days 90±14. The primary outcomes for the pilot RCT are recruitment rate, protocol adherence and patient compliance with the randomly allocated interventions. Secondary outcomes are patient functional outcomes and safety and effectiveness outcomes, which will comprise key endpoints for the future planned RCT. This pilot RCT will provide important data to inform the feasibility of conducting a future, large RCT of early versus late resumption of DOACs for atrial fibrillation stroke prophylaxis in patients newly diagnosed with SDH. The future RCT will help inform management of a commonly encountered clinical dilemma with high associated morbidity and mortality.Ethics and disseminationThis study has been approved by the research ethics board of record. It will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and regulatory requirements. Informed consent will be obtained from eligible patients or substitute decision-makers. Data from this study will inform the design of future, larger RCTs.Trial registration numberNCT05472766.

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Administration, Oral / Anticoagulants / Anticoagulants - administration & dosage / Anticoagulants - therapeutic use / Anticoagulation / Atrial Fibrillation - complications / Atrial Fibrillation - drug therapy / Cardiac arrhythmia / Female / Haematology (incl blood transfusion) / Hematoma, Subdural, Acute - complications / Hematoma, Subdural, Acute - drug therapy / Hematoma, Subdural, Chronic - complications / Hematoma, Subdural, Chronic - drug therapy / Humans / Male / Mortality / Multicenter Studies as Topic / Neurosurgery / Patients / Pilot Projects / Protocol / Randomized Controlled Trial / Randomized Controlled Trials as Topic / Stroke / Stroke - etiology / Stroke - prevention & control / Surgery / Thromboembolism / Time Factors